Any significant calorie deficit produces lean mass loss, whether it comes from surgery, diet, or medication
Clinical Evidence: GLP-1 and Cardiovascular Health Major clinical trials including SUSTAIN-6 (semaglutide) and SURPASS (tirzepatide) documented cardiovascular outcomes in patients with type 2 diabetes and obesity
The arrival of oral GLP-1 therapies for obesity, such as Novo Nordisks oral semaglutide and Lillys orforglipron in 2026 signals a seismic shift in a market dominated by injectables
The primary target of ROS is lipids in the cell membrane and lipid peroxidation (LPO) impairs cell structure and function [7]
Key limitations include variability in their physicochemical and mechanical properties, which can impact reproducibility and reliability in therapeutic settings (Moradali and Rehm, 2020
State of the art and considerations about the risk of infection